Biotechnology

Wednesday Jul 27, 2022 - 10:05 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Study Evaluating Topically Administered Ketamine Formulation

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, has reported that its recent animal study evaluating topically administered ketamine reached a positive end point: using SILO’s selected formulation and partnered, patented delivery system, the study indicated reversal of allodynia and hyperalgesia. According to the announcements, the proprietary formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, with mechanical hyperalgesia reduced…

Tuesday Jul 26, 2022 - 9:26 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled its annual shareholder meeting. The company’s 2022 Annual Meeting of Shareholders will begin at 10 a.m. ET on Aug. 15, 2022; the meeting will be held virtually. According to the announcement, notice of the annual meeting and a proxy statement containing meeting details should be available approximately July 25,…

Monday Jul 25, 2022 - 11:06 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitive proxy statement for the upcoming annual shareholder meeting to be held Wednesday, July 27, 2022. Proposals include the authorization to increase the…

Monday Jul 25, 2022 - 10:13 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it…

Friday Jul 22, 2022 - 2:15 pm

InvestorNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients,” a recent article reads. “CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC.…

Friday Jul 22, 2022 - 1:52 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology

Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic process or joint disease. Current treatment for arthritis has side…

Wednesday Jul 20, 2022 - 3:02 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during…

Wednesday Jul 20, 2022 - 2:42 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive brain cancer glioblastoma (‘GBM’),” explains a recent article. “The trial…

Wednesday Jul 20, 2022 - 1:04 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member…

Monday Jul 18, 2022 - 10:05 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its appointment of Michael Woudenberg as chief operating officer of the company, overseeing all day-to-day operations. Woudenberg previously served as senior vice president of chemistry, manufacturing and controls. For the past several years, he has been an integral part of InMed’s executive team, supporting multiple functions within…

Thursday Jul 14, 2022 - 2:00 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine,…

Thursday Jul 14, 2022 - 10:46 am

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., will be featured in a new interview aired by RedChip Companies on The RedChip Money Report(R) on Bloomberg TV at 7 p.m. Eastern Time this Saturday, July 16. Bloomberg TV is available in an estimated 73 million homes across the U.S. In the exclusive interview, Odyssey Health’s spokesperson and Pro Football Hall of Fame quarterback Brett…

Wednesday Jul 13, 2022 - 3:12 pm

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and…

Wednesday Jul 13, 2022 - 1:09 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest episode of InvestorBrandNetwork’s Stock2Me podcast. Hosted by Stuart Smith, the podcast talks with soccer play Abby Wambach, an Olympic gold medalist and member of ODYY’s sports advisory board. During the interview, Wambach discusses her soccer career and why she was drawn to…

Wednesday Jul 13, 2022 - 12:25 pm

InvestorNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that is wholly owned subsidiary, Lucid Psycheceuticals Inc., filed a provisional patent application on novel formulations of palmitoylethanolamide (“PEA”). According to the update, the new patent application is based on the results of completed preclinical animal toxicology studies and phase…

Tuesday Jul 12, 2022 - 3:35 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not…

Tuesday Jul 12, 2022 - 1:04 pm

InvestorNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a…

Tuesday Jul 12, 2022 - 11:40 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human subjects. Concussions represent an “unmet” medical need and affect millions…

Monday Jul 11, 2022 - 10:01 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to date, is expected to accelerate the clinical development path of…

Friday Jul 08, 2022 - 2:55 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients

Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine Ann Denny, an associate professor of clinical neurobiology, saying: “To…

Friday Jul 08, 2022 - 10:41 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. Calling the study results “promising,” the…

Thursday Jul 07, 2022 - 1:24 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Poised to Successfully Commercialize Its Products

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. At the moment, Odyssey’s market profile includes two medical device…

Friday Jul 01, 2022 - 1:03 pm

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Helping Individuals Make More Informed Decisions

Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune system response? Will this immunity status provide protection from the…

Wednesday Jun 29, 2022 - 10:55 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Completes Safety Evaluation of Cohort II for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. Cohort II data indicates that the drug was safe and well-tolerated. “PRV-002 continues to…

Tuesday Jun 28, 2022 - 3:00 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Pursuing Strategy Against COVID-19, Immune System-Related Maladies

Aditxt (NASDAQ: ADTX) is focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions. “Aditxt is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection,” a recent article reads. “Aditxt’s first commercial product is an…

Tuesday Jun 28, 2022 - 10:49 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when the company acquired Adelia. Reaching the milestone means that an…

Monday Jun 27, 2022 - 12:17 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Report of Annual General Meeting of Shareholders

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, is reporting on its annual general meeting of shareholders; the meeting was held online on June 23, 2022. During the meeting, seven nominees were elected as directors of the company. The new directors are Anthony Durkacz, Zeeshan Saeed, Donal Carroll, Adnan Bashir, Fernando…

Monday Jun 27, 2022 - 11:11 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has received approval from the U.S. Food and Drug Administration (“FDA”) to proceed with its phase 1/2a first-in-human clinical trial evaluating CYB003; the company has received a “may proceed” letter and investigational new drug application (“IND”) clearance from the FDA. The approval means that CYB003 will be the first novel psilocybin analog…

Friday Jun 24, 2022 - 1:00 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Sets Sights on US Phase II Clinical Trials with Focus on Military

Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or concussion. And though concussion greatly impacts military service members, there…

Thursday Jun 23, 2022 - 1:25 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has expanded its commercial evaluation license agreement (“CELA”) with the University of Maryland Baltimore (“UMB”) for its next-generation liposomal peptide targeting autoimmune diseases. “We are delighted to expand our partnership with UMB. Pre-clinical testing of these peptides has shown positive results in animal studies.…

Wednesday Jun 22, 2022 - 11:42 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today reported recent business highlights and audited financial results for its fiscal year ended March 31, 2022. In addition, the company reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. “Cybin made important progress across the board in recent months, accelerating both our pipeline of proprietary investigational…

Thursday Jun 16, 2022 - 12:16 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health Conference. The event is slated to take place at the Lotte New York Palace Hotel on June 27, 2022. Drysdale’s fireside chat will be webcast live…

Wednesday Jun 15, 2022 - 2:22 pm

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset

Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a single dose of PRV-002 or placebo followed by evaluations for abnormal responses, showed that the participants did not exhibit any severe adverse events as PRV-002…

Tuesday Jun 14, 2022 - 3:01 pm

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Added to PMLS Menu of Testing Services

Premier Medical Laboratory Services (“PMLS”), a nation-leading advanced medical diagnostics lab, today announced that it has added Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) to its menu of testing services. AditxtScore provides more clarity regarding a patient’s individual immunity profile and allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. “As new variants emerge, we want to…

Tuesday Jun 14, 2022 - 11:33 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well…

Monday Jun 13, 2022 - 1:17 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research

Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with psilocybin] patients who have Parkinson’s disease. “Silo is exploring psilocybin’s…

Friday Jun 10, 2022 - 10:32 am

InvestorNewsBreaks – Bluejay Diagnostics Inc. (NASDAQ: BJDX) Announces Continued Advancement of Symphony IL-6 Test

Bluejay Diagnostics (NASDAQ: BJDX), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, has announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test. “We are excited for the opportunity to pursue the De Novo regulatory pathway,” said Bluejay’s Chief Executive Officer Neil Dey. “This…

Friday Jun 10, 2022 - 10:25 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”). Cybin applied for IRB approval just…

Thursday Jun 09, 2022 - 1:29 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Engages IBN for Corporate Communications Expertise

Aditxt (NASDAQ: ADTX), a biotech innovation company, today announced that it has selected the corporate communications expertise of IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs, and other outreach tools to…

Tuesday Jun 07, 2022 - 12:52 pm

InvestorNewsBreaks – Why Odyssey Health Inc. (ODYY) Is ‘One to Watch’

Odyssey Health (OTC: ODYY) is a medical technology company focused on developing lifesaving products that offer technological and clinical advantages over current standards of care. Guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems, and forging strategic partnerships, the company boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices. “Odyssey has two pharmaceutical products…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions